Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Ivermectin in Adults With Severe COVID-19
NCT04602507Phase 2Terminated
- Sponsor
- Universidad CES
- Start
- Dec 2020
- Primary completion
- Dec 2021
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, double-blind trial of CHILD-IVITAB in coronavirus disease 2019 (COVID-19), sponsored by Universidad CES. Primary endpoint: Admission to the intensive care unit at 21 days. Started Dec 2020; status: terminated.
02
Drugs
CHILD-IVITAB
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT04602507.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04602507.